Somatic alterations in circulating tumor DNA (ctDNA) is also associated to remedy response or prognosis in prostate most cancers (PCa). The purpose was to characterize androgen receptor gene (AR) amplifications and mutations detected in ctDNA from victims with PCa and to extra understand the somatic genetic heterogeneity of superior prostate most cancers.
This study included a heterogeneous group of 892 victims with superior PCa (predominantly castrate-resistant prostate most cancers) with AR alterations detected in ctDNA that underwent next-generation sequencing of 54 to 73 genes by the use of Guardant360 testing (Guardant Health, Inc., Redwood City, CA).
Distribution and summary of AR alterations detected, the affiliation of AR alterations with completely different genes, and a pathway analysis are reported.The median absolute plasma copy number of AR amplifications was 3.3 (range, 1.2-165.2).
Many victims had a variety of AR mutations; a whole of 112 distinctive mutations have been acknowledged in AR, along with L702H (25%), T878A (14%), H875Y (11%), W742C (8%), W742L (4%), F877L (2%), and T878S (2%). Other ctDNA gene alterations throughout the Guardant assays included TP53 (50%), MYC (34%), BRAF (32%), PIK3CA (29%), MET (25%), CDK6 (26%), EGFR (24%), FGFR1 (21%), and APC (12%).
Many of these non-AR alterations are normally not tissue verified in numerous analysis. AR amplification cosegregated with alterations in MYC (p < .001), BRAF (p < .001), PIK3CA (p < .001), MET (p < .001), CDK6 (p < .001), EGFR (p < .001), FGFR1 (p = .391), and further. Alterations in APC have been significantly associated to mutations in AR (p < .001).Several AR alterations and concomitant non-AR alterations that affiliate with drug resistance have been detected.
These findings current additional insights into the heterogeneity of superior prostate most cancers.
NF-kB p65 Antibody |
AF6387 |
Affbiotech |
200ul |
EUR 420 |
NF-kB p65 Antibody |
AF6795 |
Affbiotech |
100ul |
EUR 420 |
NF-kB p65 Antibody |
AF0874 |
Affbiotech |
200ul |
EUR 420 |
NF-kB p65 Antibody |
48676-100ul |
SAB |
100ul |
EUR 399.6 |
NF-kB p65 Antibody |
48676-50ul |
SAB |
50ul |
EUR 286.8 |
NF-kB p65 Antibody |
BF0382 |
Affbiotech |
200ul |
EUR 540 |
pGreenFire1-NF-kB (plasmid) |
TR012PA-1 |
SBI |
10 ug |
EUR 943.2 |
|
pGreenFire1-NF-kB (virus) |
TR012VA-1 |
SBI |
>2 x 10^6 IFUs |
EUR 943.2 |
|
p65 Antibody / NF-kB |
V9229-100UG |
NSJ Bioreagents |
100ug |
EUR 499 |
Description: Proteins encoded by the v-Rel viral oncogene and its cellular homolog, c-Rel, are members of a family of transcription factors that include the two subunits of the transcription factor N B (p50 and p65) and the Drosophila maternal morphogen, dorsal. Both proteins specifically bind to DNA sequences that are the same or slight variations of the 10 bp B sequence in the immunoglobulin light chain enhancer. This same sequence is also present in a number of other cellular and viral enhancers. The DNA binding activity of NF B is activated and NF B is subsequently transported from the cytoplasm to the nucleus in cells exposed to mitogens or growth factors. cDNAs encoding precursors for two distinct proteins of the same size have been described, designated p105 and p100. The p105 precursor contains p50 at its N-terminus and a C-terminal region that when expressed as a separate molecule, designated pdI, binds to p50 and regulates its activity. |
p65 Antibody / NF-kB |
V9229-20UG |
NSJ Bioreagents |
20ug |
EUR 219 |
Description: Proteins encoded by the v-Rel viral oncogene and its cellular homolog, c-Rel, are members of a family of transcription factors that include the two subunits of the transcription factor N B (p50 and p65) and the Drosophila maternal morphogen, dorsal. Both proteins specifically bind to DNA sequences that are the same or slight variations of the 10 bp B sequence in the immunoglobulin light chain enhancer. This same sequence is also present in a number of other cellular and viral enhancers. The DNA binding activity of NF B is activated and NF B is subsequently transported from the cytoplasm to the nucleus in cells exposed to mitogens or growth factors. cDNAs encoding precursors for two distinct proteins of the same size have been described, designated p105 and p100. The p105 precursor contains p50 at its N-terminus and a C-terminal region that when expressed as a separate molecule, designated pdI, binds to p50 and regulates its activity. |
p65 Antibody / NF-kB |
V9229SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 499 |
Description: Proteins encoded by the v-Rel viral oncogene and its cellular homolog, c-Rel, are members of a family of transcription factors that include the two subunits of the transcription factor N B (p50 and p65) and the Drosophila maternal morphogen, dorsal. Both proteins specifically bind to DNA sequences that are the same or slight variations of the 10 bp B sequence in the immunoglobulin light chain enhancer. This same sequence is also present in a number of other cellular and viral enhancers. The DNA binding activity of NF B is activated and NF B is subsequently transported from the cytoplasm to the nucleus in cells exposed to mitogens or growth factors. cDNAs encoding precursors for two distinct proteins of the same size have been described, designated p105 and p100. The p105 precursor contains p50 at its N-terminus and a C-terminal region that when expressed as a separate molecule, designated pdI, binds to p50 and regulates its activity. |
p65 Antibody / NF-kB |
V9238-100UG |
NSJ Bioreagents |
100ug |
EUR 499 |
Description: Proteins encoded by the v-Rel viral oncogene and its cellular homolog, c-Rel, are members of a family of transcription factors that include the two subunits of the transcription factor N B (p50 and p65) and the Drosophila maternal morphogen, dorsal. Both proteins specifically bind to DNA sequences that are the same or slight variations of the 10 bp B sequence in the immunoglobulin light chain enhancer. This same sequence is also present in a number of other cellular and viral enhancers. The DNA binding activity of NF B is activated and NF B is subsequently transported from the cytoplasm to the nucleus in cells exposed to mitogens or growth factors. cDNAs encoding precursors for two distinct proteins of the same size have been described, designated p105 and p100. The p105 precursor contains p50 at its N-terminus and a C-terminal region that when expressed as a separate molecule, designated pdI, binds to p50 and regulates its activity. |
p65 Antibody / NF-kB |
V9238-20UG |
NSJ Bioreagents |
20ug |
EUR 219 |
Description: Proteins encoded by the v-Rel viral oncogene and its cellular homolog, c-Rel, are members of a family of transcription factors that include the two subunits of the transcription factor N B (p50 and p65) and the Drosophila maternal morphogen, dorsal. Both proteins specifically bind to DNA sequences that are the same or slight variations of the 10 bp B sequence in the immunoglobulin light chain enhancer. This same sequence is also present in a number of other cellular and viral enhancers. The DNA binding activity of NF B is activated and NF B is subsequently transported from the cytoplasm to the nucleus in cells exposed to mitogens or growth factors. cDNAs encoding precursors for two distinct proteins of the same size have been described, designated p105 and p100. The p105 precursor contains p50 at its N-terminus and a C-terminal region that when expressed as a separate molecule, designated pdI, binds to p50 and regulates its activity. |
p65 Antibody / NF-kB |
V9238SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 499 |
Description: Proteins encoded by the v-Rel viral oncogene and its cellular homolog, c-Rel, are members of a family of transcription factors that include the two subunits of the transcription factor N B (p50 and p65) and the Drosophila maternal morphogen, dorsal. Both proteins specifically bind to DNA sequences that are the same or slight variations of the 10 bp B sequence in the immunoglobulin light chain enhancer. This same sequence is also present in a number of other cellular and viral enhancers. The DNA binding activity of NF B is activated and NF B is subsequently transported from the cytoplasm to the nucleus in cells exposed to mitogens or growth factors. cDNAs encoding precursors for two distinct proteins of the same size have been described, designated p105 and p100. The p105 precursor contains p50 at its N-terminus and a C-terminal region that when expressed as a separate molecule, designated pdI, binds to p50 and regulates its activity. |
NF-kB p65 Blocking Peptide |
DF7003-BP |
Affbiotech |
1mg |
EUR 234 |
NF-kB p65 Conjugated Antibody |
C48676 |
SAB |
100ul |
EUR 476.4 |
NF-kB p65 Blocking Peptide |
AF0874-BP |
Affbiotech |
1mg |
EUR 234 |
NF-kB p65 Rabbit pAb |
A11202-100ul |
Abclonal |
100 ul |
EUR 369.6 |
NF-kB p65 Rabbit pAb |
A11202-200ul |
Abclonal |
200 ul |
EUR 550.8 |
NF-kB p65 Rabbit pAb |
A11202-20ul |
Abclonal |
20 ul |
EUR 219.6 |
NF-kB p65 Rabbit pAb |
A11202-50ul |
Abclonal |
50 ul |
EUR 267.6 |
NF-kB p65 Rabbit pAb |
A11204-100ul |
Abclonal |
100 ul |
EUR 369.6 |
NF-kB p65 Rabbit pAb |
A11204-200ul |
Abclonal |
200 ul |
EUR 550.8 |
NF-kB p65 Rabbit pAb |
A11204-20ul |
Abclonal |
20 ul |
EUR 219.6 |
NF-kB p65 Rabbit pAb |
A11204-50ul |
Abclonal |
50 ul |
EUR 267.6 |
NF-kB p65 Mouse mAb |
A10609 |
Abclonal |
20 μL |
EUR 18 |
NF-kB p65 Mouse mAb |
A10609-100ul |
Abclonal |
100 ul |
EUR 460.8 |
NF-kB p65 Mouse mAb |
A10609-200ul |
Abclonal |
200 ul |
EUR 664.8 |
NF-kB p65 Mouse mAb |
A10609-20ul |
Abclonal |
20 ul |
Ask for price |
NF-kB p65 Mouse mAb |
A10609-50ul |
Abclonal |
50 ul |
EUR 318 |
NF-kB p100 (pS872) Antibody |
abx011250-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
NF-kB p65 (pS281) Antibody |
abx011264-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
NF-kB p65 (pS529) Antibody |
abx011265-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
NF-kB p65 (pS311) Antibody |
abx011266-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
NF-kB p65 (pS536) Antibody |
abx011269-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
NF-kB p65 (pS276) Antibody |
abx011270-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
NF-kB p65 (pS468) Antibody |
abx011271-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
NF-kB p65 (pT254) Antibody |
abx011272-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
NF-kB p65 (pT435) Antibody |
abx011273-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
NF-kB p65 Rabbit pAb |
A2547-100ul |
Abclonal |
100 ul |
EUR 369.6 |
NF-kB p65 Rabbit pAb |
A2547-200ul |
Abclonal |
200 ul |
EUR 550.8 |
NF-kB p65 Rabbit pAb |
A2547-20ul |
Abclonal |
20 ul |
EUR 219.6 |
NF-kB p65 Rabbit pAb |
A2547-50ul |
Abclonal |
50 ul |
EUR 267.6 |
NF-kB p65 Rabbit pAb |
A16271-100ul |
Abclonal |
100 ul |
EUR 369.6 |
NF-kB p65 Rabbit pAb |
A16271-200ul |
Abclonal |
200 ul |
EUR 550.8 |
NF-kB p65 Rabbit pAb |
A16271-20ul |
Abclonal |
20 ul |
EUR 219.6 |
NF-kB p65 Rabbit pAb |
A16271-50ul |
Abclonal |
50 ul |
EUR 267.6 |
NF-kB p65 Rabbit pAb |
A0450-100ul |
Abclonal |
100 ul |
EUR 369.6 |
NF-kB p65 Rabbit pAb |
A0450-200ul |
Abclonal |
200 ul |
EUR 550.8 |
NF-kB p65 Rabbit pAb |
A0450-20ul |
Abclonal |
20 ul |
Ask for price |
NF-kB p65 Rabbit pAb |
A0450-50ul |
Abclonal |
50 ul |
Ask for price |
NF-kB p65 Blocking Peptide |
BF0382-BP |
Affbiotech |
1mg |
EUR 234 |
NF-kB p65 Polyclonal Antibody |
A71090-050 |
EpiGentek |
50 ul |
EUR 377.3 |
NF-kB p65 Polyclonal Antibody |
A71090-100 |
EpiGentek |
100 ul |
EUR 577.5 |
NF-kB p65 Polyclonal Antibody |
A71091-050 |
EpiGentek |
50 ul |
EUR 302.5 |
NF-kB p65 Polyclonal Antibody |
A71091-100 |
EpiGentek |
100 ul |
EUR 423.5 |
NF-kB p65 Polyclonal Antibody |
A71092-050 |
EpiGentek |
50 ul |
EUR 302.5 |
NF-kB p65 Polyclonal Antibody |
A71092-100 |
EpiGentek |
100 ul |
EUR 423.5 |
NF-kB p65 Polyclonal Antibody |
A71094-050 |
EpiGentek |
50 ul |
EUR 302.5 |
NF-kB p65 Polyclonal Antibody |
A71094-100 |
EpiGentek |
100 ul |
EUR 423.5 |
NF-kB p65 Polyclonal Antibody |
A71090 |
EpiGentek |
|
|
NF-kB p65 Polyclonal Antibody |
A71091 |
EpiGentek |
|
|
NF-kB p65 Polyclonal Antibody |
A71092 |
EpiGentek |
|
|
NF-kB p65 Polyclonal Antibody |
A71094 |
EpiGentek |
|
|
Phospho-NF-kB p65 (Ser276) Antibody |
AF3387 |
Affbiotech |
200ul |
EUR 420 |
Phospho-NF-kB p65 (Ser529) Antibody |
AF3388 |
Affbiotech |
200ul |
EUR 420 |
Phospho-NF-kB p65 (Ser311) Antibody |
AF3389 |
Affbiotech |
200ul |
EUR 420 |
Phospho-NF-kB p65 (Ser468) Antibody |
AF3390 |
Affbiotech |
200ul |
EUR 420 |
Phospho-NF-kB p65 (Thr254) Antibody |
AF3391 |
Affbiotech |
200ul |
EUR 420 |
Phospho-NF-kB p65 (Thr435) Antibody |
AF3392 |
Affbiotech |
200ul |
EUR 420 |
Phospho-NF-kB p65 (Ser281) Antibody |
AF3393 |
Affbiotech |
200ul |
EUR 420 |
Phospho-NF-kB p65 (Ser536) Antibody |
AF2006 |
Affbiotech |
200ul |
EUR 420 |
NF-kB p65 Polyclonal Conjugated Antibody |
C27518 |
SAB |
100ul |
EUR 476.4 |
NF-kB p65 (Phospho-S529) Antibody |
13347-100ul |
SAB |
100ul |
EUR 399.6 |
NF-kB p65 (Phospho-S529) Antibody |
13347-50ul |
SAB |
50ul |
EUR 286.8 |
NF-kB p65 recombinant monoclonal antibody |
A5075 |
Bimake |
100ul X 3 |
EUR 714 |
|
Description: A recombinant monoclonal antibody from rabbit against human NF-kB p65 for WB, IHC, IF,ELISA |
NF-kB p100 / p52 (pS865) Antibody |
abx011251-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
NF-kB p100 / p52 (pS869) Antibody |
abx011252-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
NF-kB p105 / p50 (pS932) Antibody |
abx011254-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
NF-kB p105 / p50 (pS893) Antibody |
abx011255-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
NF-kB p105 / p50 (pS337) Antibody |
abx011256-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
NF-kB p105 / p50 (pS927) Antibody |
abx011257-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
NF-kB p105 / p50 (pS907) Antibody |
abx011259-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
Anti-NF-kB p65/RELA Antibody |
A00284-1 |
BosterBio |
100ug/vial |
EUR 400.8 |
Anti-NF-kB p65/RELA Antibody |
PA1125 |
BosterBio |
100ug/vial |
EUR 352.8 |
Anti-NF-kB p65/RELA Antibody |
PA1669 |
BosterBio |
100ug/vial |
EUR 400.8 |
Anti-NF-kB p65/RELA Antibody |
PB9087 |
BosterBio |
100ug/vial |
EUR 352.8 |
Anti-NF-kB p65/RELA Antibody |
PB9324 |
BosterBio |
100ug/vial |
EUR 352.8 |
pGreenFire1-NF-kB (plasmid)+ EF1-Neo |
TR012PA-N |
SBI |
10 ug |
EUR 943.2 |
|
pGreenFire1-NF-kB (plasmid)+ EF1-Puro |
TR012PA-P |
SBI |
10 ug |
EUR 943.2 |
|
pGreenFire1-NF-kB (virus) + EF1-Neo |
TR012VA-N |
SBI |
>2 x 10^6 IFUs |
EUR 943.2 |
|
pGreenFire1-NF-kB (virus) + EF1-Puro |
TR012VA-P |
SBI |
>2 x 10^6 IFUs |
EUR 943.2 |
|
Rat Nuclear Factor-kB P65 (NF-kB p65) CLIA Kit |
abx196083-96tests |
Abbexa |
96 tests |
EUR 990 |
|
ELISA kit for Human Nuclear factor-KB p65 (NF-KB p65) |
KTE60811-48T |
Abbkine |
48T |
EUR 424.8 |
|
Description: Quantitative sandwich ELISA for measuring Human Nuclear factor-KB p65 (NF-KB p65) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
ELISA kit for Human Nuclear factor-KB p65 (NF-KB p65) |
KTE60811-5platesof96wells |
Abbkine |
5 plates of 96 wells |
EUR 2702.4 |
|
Description: Quantitative sandwich ELISA for measuring Human Nuclear factor-KB p65 (NF-KB p65) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
ELISA kit for Human Nuclear factor-KB p65 (NF-KB p65) |
KTE60811-96T |
Abbkine |
96T |
EUR 686.4 |
|
Description: Quantitative sandwich ELISA for measuring Human Nuclear factor-KB p65 (NF-KB p65) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
ELISA kit for Mouse Nuclear factor-KB p65 (NF-KB p65) |
KTE70510-48T |
Abbkine |
48T |
EUR 424.8 |
|
Description: Quantitative sandwich ELISA for measuring Mouse Nuclear factor-KB p65 (NF-KB p65) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
ELISA kit for Mouse Nuclear factor-KB p65 (NF-KB p65) |
KTE70510-5platesof96wells |
Abbkine |
5 plates of 96 wells |
EUR 2702.4 |
|
Description: Quantitative sandwich ELISA for measuring Mouse Nuclear factor-KB p65 (NF-KB p65) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
ELISA kit for Mouse Nuclear factor-KB p65 (NF-KB p65) |
KTE70510-96T |
Abbkine |
96T |
EUR 686.4 |
|
Description: Quantitative sandwich ELISA for measuring Mouse Nuclear factor-KB p65 (NF-KB p65) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
NF-kB p65 (Phospho-S529) Conjugated Antibody |
C13347 |
SAB |
100ul |
EUR 476.4 |
Phospho-NF-kB p105 (Ser903) Blocking Peptide |
AF8013-BP |
Affbiotech |
1mg |
EUR 234 |
Phospho-NF-kB p105 (Ser923) Blocking Peptide |
AF8014-BP |
Affbiotech |
1mg |
EUR 234 |
Phospho-NF-kB p100 (Ser872) Blocking Peptide |
AF3375-BP |
Affbiotech |
1mg |
EUR 234 |
[KO Validated] NF-kB p65 Rabbit pAb |
A11201-100ul |
Abclonal |
100 ul |
EUR 492 |
[KO Validated] NF-kB p65 Rabbit pAb |
A11201-200ul |
Abclonal |
200 ul |
EUR 685.2 |
[KO Validated] NF-kB p65 Rabbit pAb |
A11201-20ul |
Abclonal |
20 ul |
EUR 265.2 |
[KO Validated] NF-kB p65 Rabbit pAb |
A11201-50ul |
Abclonal |
50 ul |
EUR 344.4 |
[KO Validated] NF-kB p65 Polyclonal Antibody |
27518-100ul |
SAB |
100ul |
EUR 302.4 |
[KO Validated] NF-kB p65 Polyclonal Antibody |
27518-50ul |
SAB |
50ul |
EUR 224.4 |
[KO Validated] NF-kB p65 Rabbit mAb |
A19653 |
Abclonal |
20 μL |
EUR 18 |
[KO Validated] NF-kB p65 Rabbit mAb |
A19653-100ul |
Abclonal |
100 ul |
EUR 492 |
[KO Validated] NF-kB p65 Rabbit mAb |
A19653-200ul |
Abclonal |
200 ul |
EUR 685.2 |
[KO Validated] NF-kB p65 Rabbit mAb |
A19653-20ul |
Abclonal |
20 ul |
EUR 265.2 |
[KO Validated] NF-kB p65 Rabbit mAb |
A19653-50ul |
Abclonal |
50 ul |
EUR 344.4 |
Anti-NF-kB p65 Antibody (Clone#AMC0222) |
A2000-100 |
Biovision |
100 µl |
EUR 405.6 |
NF-kB p65 highly active Recombinant Protein |
90-348 |
ProSci |
2 ug |
EUR 600.9 |
Description: NF-kappaB is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappaB is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The heterodimeric p65-p50 complex is the most abundant complex. The dimers bind at kappaB sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappaB sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappaB complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappaB inhibitor (I-kappaB) family. In a conventional activation pathway, I-kappaB is phosphorylated by I-kappaB kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappaB complex which translocates to the nucleus. NF-kappaB heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappaB p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappaB complex. |
NF-kB p50 highly active Recombinant Protein |
90-349 |
ProSci |
2 ug |
EUR 632.4 |
Description: NF-kappaB is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappaB is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The heterodimeric p65-p50 complex is the most abundant complex. The dimers bind at kappaB sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappaB sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappaB complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappaB inhibitor (I-kappaB) family. In a conventional activation pathway, I-kappaB is phosphorylated by I-kappaB kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappaB complex which translocates to the nucleus. NF-kappaB heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappaB p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. |
Polyclonal NF-KB p100 Antibody (Ab-869) |
APR05373G |
Leading Biology |
0.1ml |
EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NF-KB p100 (Ab-869). This antibody is tested and proven to work in the following applications: |
Phospho-NF-kB p65-S311 Rabbit pAb |
AP0445-100ul |
Abclonal |
100 ul |
EUR 460.8 |
Phospho-NF-kB p65-S311 Rabbit pAb |
AP0445-200ul |
Abclonal |
200 ul |
EUR 664.8 |
Phospho-NF-kB p65-S311 Rabbit pAb |
AP0445-20ul |
Abclonal |
20 ul |
EUR 219.6 |
Phospho-NF-kB p65-S311 Rabbit pAb |
AP0445-50ul |
Abclonal |
50 ul |
EUR 318 |
Phospho-NF-kB p65-S536 Rabbit pAb |
AP0475-100ul |
Abclonal |
100 ul |
EUR 460.8 |
Phospho-NF-kB p65-S536 Rabbit pAb |
AP0475-200ul |
Abclonal |
200 ul |
EUR 664.8 |
Phospho-NF-kB p65-S536 Rabbit pAb |
AP0475-20ul |
Abclonal |
20 ul |
EUR 219.6 |
Phospho-NF-kB p65-S536 Rabbit pAb |
AP0475-50ul |
Abclonal |
50 ul |
EUR 318 |
Phospho-NF-kB p65-T254 Rabbit pAb |
AP0122-100ul |
Abclonal |
100 ul |
EUR 460.8 |
Phospho-NF-kB p65-T254 Rabbit pAb |
AP0122-200ul |
Abclonal |
200 ul |
EUR 664.8 |
Phospho-NF-kB p65-T254 Rabbit pAb |
AP0122-20ul |
Abclonal |
20 ul |
Ask for price |
Phospho-NF-kB p65-T254 Rabbit pAb |
AP0122-50ul |
Abclonal |
50 ul |
EUR 318 |
Phospho-NF-kB p65-S276 Rabbit pAb |
AP0123-100ul |
Abclonal |
100 ul |
EUR 460.8 |
Phospho-NF-kB p65-S276 Rabbit pAb |
AP0123-200ul |
Abclonal |
200 ul |
EUR 664.8 |
Phospho-NF-kB p65-S276 Rabbit pAb |
AP0123-20ul |
Abclonal |
20 ul |
EUR 219.6 |
The purpose was to characterize androgen receptor gene (AR) amplifications and mutations detected in circulating tumor DNA (ctDNA) from victims with prostate most cancers in relation to non-AR gene alterations detected throughout the ctDNA panorama.
The study included 892 victims with prostate most cancers with AR alterations in ctDNA. AR alterations have been significantly associated to completely different gene alterations detected in ctDNA.
The widespread AR mutations found are linked to resistance to abiraterone, enzalutamide, or bicalutamide. Characterization of the circulating AR panorama and gene alterations provides potential additional notion into the somatic genetic heterogeneity of superior prostate most cancers.